About the Company
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, the company believes that its product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.
Employees
44
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MRKR News
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study ...
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Dr. Vera will present an overview of Marker’s advancements and clinical development programs on Tuesday, March 26, 2024, at 10 AM EDT. The presentation will be available for replay starting March 26, ...
Marker Therapeutics GAAP EPS of -$1.59, revenue of $3.31M
Marker Therapeutics press release ( NASDAQ: MRKR ): FY GAAP EPS of -$1.59. At December 31, 2023, Marker had cash and cash equivalents of $15.1 million. The company believes that its existing cash and ...
Judge Dismisses Lawsuit Over Removal of Marker Dedicated to Communist Party Leader
A judge has dismissed a lawsuit brought against the state of New Hampshire after government officials removed a historical ...
FDA authorizes Waltham company’s Covid prevention drug
The U.S. Food and Drug Administration gave emergency use authorization Friday to a local company’s drug to prevent Covid-19 in people who are immunocompromised. The drug was made by Invivyd Inc.
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
The poster presentation highlights ALG-055009 Phase 1 data that showed multiple-ascending doses (MAD) over 14 days in hyperlipidemic subjects produced favorable, dose-dependent pharmacodynamic effects ...
Mouse Models and Markers for Cerebral Amyloid Angiopathy, ARIA
With people now being treated with amyloid immunotherapy in the clinic, reducing the risk of ARIA has taken on a new sense of urgency. This inflammatory side effect occurs in people who have amyloid ...
Northwest Biotherapeutics gets grant for method for deriving immature dendritic cells from monocytic precursors
Generate immature dendritic cells for immunotherapy with Northwest Biotherapeutics Inc's patented method using GM-CSF alone. Learn more about this innovative cancer treatment approach.
The Andy Westcott Band Concert at The Marker Key West Harbor Resort
Make a splash at The Marker Key West Harbor Resort's pool party on Saturday, April 13 from 1 - 4 p.m. and dance to the tunes ...
Marker dedication reset for Temple cemetery
A Texas Historic Marker at an obscure community cemetery near the intersection of Kegley Road and Charter Oak Drive will be ...
Middle Passage Marker in Port Arthur commemorates ancestors, provides history of local slave trade
Getting your Trinity Audio player ready... For Port Arthur’s Gail Pellum, the newly unveiled Middle Passage Marker signifies healing and a time to reflect. “It’s important to know where you come from ...
Loading the latest forecasts...